ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy

Cell Reports

Volumn 13, Issue 3, 2015, Pages 489-494

  Wielenga, Mattheus C B ^a   Colak, Selcuk ^a   Heijmans, Jarom ^a   van Lidth de Jeude, Jooske F ^a   Rodermond, Hans M ^a   Paton, James C ^b   Paton, Adrienne W ^b   Vermeulen, Louis ^a   Medema, Jan Paul ^a   van den Brink, Gijs R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN; SALUBRINAL; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; COLON CANCER; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UNFOLDED PROTEIN RESPONSE; ANIMAL; COLONIC NEOPLASMS; CYTOLOGY; DRUG EFFECTS; METABOLISM; MULTICELLULAR SPHEROID;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; COLONIC NEOPLASMS; ENDOPLASMIC RETICULUM STRESS; HUMANS; MICE; NEOPLASTIC STEM CELLS; ORGANOPLATINUM COMPOUNDS; SPHEROIDS, CELLULAR; UNFOLDED PROTEIN RESPONSE;

EID: 84944686104     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.016     Document Type: Article

References (26)

1. Barker N., Ridgway R.A., van Es J.H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A.R., Sansom O.J., Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.
2. Boyce M., Bryant K.F., Jousse C., Long K., Harding H.P., Scheuner D., Kaufman R.J., Ma D., Coen D.M., Ron D., Yuan J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
3. Colak S., Medema J.P. Cancer stem cells--important players in tumor therapy resistance. FEBS J. 2014, 281:4779-4791.
4. Colak S., Zimberlin C.D., Fessler E., Hogdal L., Prasetyanti P.R., Grandela C.M., Letai A., Medema J.P. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014, 21:1170-1177.
5. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
6. de Sousa E Melo F., Colak S., Buikhuisen J., Koster J., Cameron K., de Jong J.H., Tuynman J.B., Prasetyanti P.R., Fessler E., van den Bergh S.P., et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011, 9:476-485.
7. Heijmans J., van Lidth de Jeude J.F., Koo B.K., Rosekrans S.L., Wielenga M.C., van de Wetering M., Ferrante M., Lee A.S., Onderwater J.J., Paton J.C., et al. ER stress causes rapid loss of intestinal epithelial stemness through activation of the unfolded protein response. Cell Rep. 2013, 3:1128-1139.
8. Hoey T., Yen W.C., Axelrod F., Basi J., Donigian L., Dylla S., Fitch-Bruhns M., Lazetic S., Park I.K., Sato A., et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
9. Hu Y., Smyth G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 2009, 347:70-78.
10. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., Fields J.Z., Wicha M.S., Boman B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69:3382-3389.
11. Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010, 1:387-395.
12. Kemper K., Prasetyanti P.R., De Lau W., Rodermond H., Clevers H., Medema J.P. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells 2012, 30:2378-2386.
13. Lombardo Y., Scopelliti A., Cammareri P., Todaro M., Iovino F., Ricci-Vitiani L., Gulotta G., Dieli F., de Maria R., Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 140:297-309.
14. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
15. Paton A.W., Beddoe T., Thorpe C.M., Whisstock J.C., Wilce M.C., Rossjohn J., Talbot U.M., Paton J.C. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 2006, 443:548-552.
16. Prasetyanti P.R., Zimberlin C.D., Bots M., Vermeulen L., Melo Fde.S., Medema J.P. Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. Mol. Cancer 2013, 12:126.
17. Ricci-Vitiani L., Lombardi D.G., Signore M., Biffoni M., Pallini R., Parati E., Peschle C., De Maria R. Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. Cell Death Differ. 2007, 14:876-878.
18. Rich J.N., Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007, 1:353-355.
19. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
20. Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J.V., Chomienne C., Ishikawa F., Schuringa J.J., Stassi G., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer 2012, 12:767-775.
21. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
22. van Galen P., Kreso A., Mbong N., Kent D.G., Fitzmaurice T., Chambers J.E., Xie S., Laurenti E., Hermans K., Eppert K., et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature 2014, 510:268-272.
23. Vermeulen L., De Sousa E Melo F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
24. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
25. Wang J.C. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 2007, 1:497-501.
26. Zeuner A., Todaro M., Stassi G., De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 2014, 15:692-705.